Immunomedics Inc. on Wednesday said it has applied to theCommittee for Proprietary Medicinal Products for approval tomarket its ImmuRAID CEA colorectal cancer imaging agent inthe European Community nations. CPMP approval is requiredbefore individual country approval can be obtained.

ImmuRAID consists of an injectable monoclonal antibodyfragment that is labeled with the technetium-99 radioisotope.

The Warren, N.J., company applied for U.S. marketing approvallast April and for Canadian approval in February. There were300,000 new cases of colorectal cancer in Europe and NorthAmerica last year.

(c) 1997 American Health Consultants. All rights reserved.